Hepatitis C virus testing in a clinical HIV cohort in Ontario, Canada, 2000 to 2015.
Coinfection/epidemiology
HIV infections/epidemiology*
HIV‐HCV co‐infection
hepatitis C virus testing
hepatitis C/epidemiology*
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
19
01
2021
revised:
11
06
2021
accepted:
26
07
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
HIV-positive individuals may acquire HCV via injection drug use (IDU) and condomless anal sex. HIV care provides opportunities for HCV testing and cure with direct-acting antiviral agents (DAAs). We analyzed data from the Ontario HIV Treatment Network Cohort Study. Among those not HCV-positive or diagnosed previously (n = 4586), we used Cox regression to test the rates of ever HCV testing (serological or RNA) in HIV care by DAA era (pre-DAA: 2000-2010; after DAA: 2011-2015) and compared the proportion diagnosed with HCV. We identified correlates of annual proportions of serological testing using Poisson generalized estimating equations. After DAA vs pre-DAA, the hazard rate ratio (95% CI) of ever HCV testing was 1.70 (1.59, 1.81). The proportion (95% CI) tested annually increased from 9.2% (8.0%, 10.7%) in 2000 to 39.1% (37.1%, 41.1%) in 2015 ( Annual HCV testing increased over time with higher testing among those reporting sexual or IDU risk factors, but fell short of clinical guidelines. Targeted interventions to boost testing may be needed to close these gaps and reach WHO 2030 HCV elimination targets.
Sections du résumé
BACKGROUND
BACKGROUND
HIV-positive individuals may acquire HCV via injection drug use (IDU) and condomless anal sex. HIV care provides opportunities for HCV testing and cure with direct-acting antiviral agents (DAAs).
METHODS
METHODS
We analyzed data from the Ontario HIV Treatment Network Cohort Study. Among those not HCV-positive or diagnosed previously (n = 4586), we used Cox regression to test the rates of ever HCV testing (serological or RNA) in HIV care by DAA era (pre-DAA: 2000-2010; after DAA: 2011-2015) and compared the proportion diagnosed with HCV. We identified correlates of annual proportions of serological testing using Poisson generalized estimating equations.
RESULTS
RESULTS
After DAA vs pre-DAA, the hazard rate ratio (95% CI) of ever HCV testing was 1.70 (1.59, 1.81). The proportion (95% CI) tested annually increased from 9.2% (8.0%, 10.7%) in 2000 to 39.1% (37.1%, 41.1%) in 2015 (
DISCUSSION
CONCLUSIONS
Annual HCV testing increased over time with higher testing among those reporting sexual or IDU risk factors, but fell short of clinical guidelines. Targeted interventions to boost testing may be needed to close these gaps and reach WHO 2030 HCV elimination targets.
Identifiants
pubmed: 34568583
doi: 10.1002/hsr2.358
pii: HSR2358
pmc: PMC8449285
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e358Investigateurs
Abigail Kroch
(A)
Ann Burchell
(A)
Sergio Rueda
(S)
Gordon Arbess
(G)
Jeffrey Cohen
(J)
Curtis Cooper
(C)
Elizabeth Lavoie
(E)
Fred Crouzat
(F)
Nisha Andany
(N)
Sharon Walmsley
(S)
Michael Silverman
(M)
Roger Sandre
(R)
Wangari Tharao
(W)
Holly Gauvin
(H)
Fiona Smaill
(F)
Jorge Martinez-Cajas
(J)
Informations de copyright
© 2021 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
None to declare.
Références
Can Commun Dis Rep. 2014 Dec 18;40(19):429-436
pubmed: 29769874
MMWR Recomm Rep. 1999 Aug 20;48(RR-10):1-59, 61-6
pubmed: 10499670
Int J Epidemiol. 2013 Apr;42(2):402-11
pubmed: 22345312
Am J Public Health. 2015 Aug;105(8):1604-10
pubmed: 26066920
Clin Infect Dis. 2014 Jan;58(1):e1-34
pubmed: 24235263
Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S63-8
pubmed: 16265616
J Viral Hepat. 2018 Dec;25(12):1472-1480
pubmed: 30047625
Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):17-22
pubmed: 25798149
Can J Infect Dis Med Microbiol. 2014 Nov-Dec;25(6):311-20
pubmed: 25587293
BMC Public Health. 2010 Apr 29;10:225
pubmed: 20429917
Open Med. 2009;3(4):e184-95
pubmed: 21688755
BMC Med Res Methodol. 2013 Mar 05;13:31
pubmed: 23496868